The Genetics Podcast
The Genetics Podcast
Sano Genetics
EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp
42 minutes Posted Nov 12, 2026 at 12:00 pm.
Intro to The Genetics Podcast00:58 Welcome to Joe 01:47 Joe’s career in HIV genetics and his move into neurology06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau21711:04 Why p-tau217 works as a scalable Alzheimer’s blood test12:35 How p-tau217 triages patients and what it can’t tell clinicians14:08 APOE testing demand and why it predicts risk without being definitive17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau21729:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for34:27 How Labcorp decides which neurology biomarkers to launch and when38:12 Future potential for migraine biomarkers that can guide treatment choices41:07 Closing remarks
0:00
42:14
Download MP3
Show notes
This week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.Show Notes0:00 Intro to The Genetics Podcast00:58 Welcome to Joe 01:47 Joe’s career in HIV genetics and his move into neurology06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau21711:04 Why p-tau217 works as a scalable Alzheimer’s blood test12:35 How p-tau217 triages patients and what it can’t tell clinicians14:08 APOE testing demand and why it predicts risk without being definitive17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau21729:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for34:27 How Labcorp decides which neurology biomarkers to launch and when38:12 Future potential for migraine biomarkers that can guide treatment choices41:07 Closing remarks